An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk. - Wikidata - awgldk - TriplyDB

An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk.

An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk.

http://www.wikidata.org/entity/Q33925329

about

Fixed-dose combination therapy for the prevention of cardiovascular disease Fixed-dose combination therapy for the prevention of cardiovascular disease Multifactorial Prevention of Cardiovascular Disease in Patients with Hypertension: the Cardiovascular Polypill Angiotensin converting enzyme inhibitor and HMG-CoA reductase inhibitor as adjunct treatment for persons with HIV infection: a feasibility randomized trial Patent and exclusivity status of essential medicines for non-communicable disease Prioritizing risk factors to identify preventive interventions for economic assessment Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases.A randomised controlled trial of a consumer-focused e-health strategy for cardiovascular risk management in primary care: the Consumer Navigation of Electronic Cardiovascular Tools (CONNECT) study protocol.Strengths and Limitations of Using the Polypill in Cardiovascular Prevention.Prehypertension: Underlying pathology and therapeutic options.Polypill therapy, subclinical atherosclerosis, and cardiovascular events-implications for the use of preventive pharmacotherapy: MESA (Multi-Ethnic Study of Atherosclerosis)Randomized Polypill crossover trial in people aged 50 and over.Medical care and payment for diabetes in China: enormous threat and great opportunity.The efficacy and tolerability of 'polypills': meta-analysis of randomised controlled trials.Interventions to improve adherence to lipid-lowering medication.Management of NCD in low- and middle-income countries.Bisoprolol and bisoprolol-valsartan compatibility studied by differential scanning calorimetry, nuclear magnetic resonance and X-ray powder diffractometry.Screening for cardiovascular disease using age alone: reflections on a paper peer-reviewed as both 'radical' and 'unsurprising'.Macroeconomic implications of population ageing and selected policy responses.[Management of different cardiovascular risk factors with a combination tablet (polypill)].The impact of aspirin, statins and ACE-inhibitors on the presentation of colorectal neoplasia in a colorectal cancer screening programme.Single-pill combinations: a therapeutic option or necessity for vascular risk treatment?Prevalence, awareness and risk factors of hypertension in a large cohort of Iranian adult population.Could patents interfere with the development of a cardiovascular polypill?The cardiovascular polypill in high-risk patients.Population-level changes to promote cardiovascular health.A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke.Reducing residual risk: modern pharmacochemistry meets old-fashioned lifestyle and adherence improvement.Effect of Pollypill on cardiovascular parameters: Systematic review and meta-analysis.Integrated preclinical cardiovascular prevention: a new paradigm to face growing challenges of cardiovascular disease.Improving cardiovascular protection: focus on a cardiovascular polypill.The polypill: An effective approach to increasing adherence and reducing cardiovascular event risk.Assessing patterns of use of cardio-protective polypill component medicines in Australian women.Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease.Polypill is not a 'vaccine-like' solution for primary cardiovascular disease prevention in all parts of the world.An epidemic of coronary heart disease.Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.A new method to evaluate the dose-effect relationship of a TCM formula Gegen Qinlian Decoction: "Focus" mode of integrated biomarkers.Polypill treatments for cardiovascular diseases.Stroke Minimization through Additive Anti-atherosclerotic Agents in Routine Treatment (SMAART): study protocol for a randomized controlled trial.

P2860

Q24195065-B4ADB124-D6A7-4921-8B3A-6B05CE05707E Q24198070-F3C5258B-3C84-4E2C-8ADC-2040BA3A0994 Q26753102-F0831578-3354-40D4-B010-D7C0F1AD1025 Q28484460-85AF83A1-906D-4CFD-8DF7-206802CA432D Q28485430-9A2D7C23-8B0E-46BE-BB65-9C7BDE78AA97 Q28731348-C79F7B7F-3737-4336-922D-04B3193BD48F Q30235416-1CF6B598-82CF-47F2-9280-A6F696994928 Q33440536-17972AD3-E6BD-4F34-AA2E-83988D877C7A Q33581084-AE8AB336-398C-4462-8041-263EFE81FAB0 Q34179007-5E321C11-B277-4231-8DD8-057F2496E30E Q34240747-7BC2B4D7-DF92-454E-B0AA-01F22477B8FB Q34345933-BBDEB544-4D5F-452A-9563-7F4E740EF4BE Q34437761-D3D0BF44-E60D-4FEE-BB64-943386774CFC Q34533125-C939C7FB-CA5B-4AFA-B0DD-DFD2B1728ABA Q34547763-9521ADB6-4F54-4D1C-935A-3ECA715FDF64 Q34987612-60E66D25-F754-4252-8D3F-183CA2CCED93 Q34990288-B799B9FD-22D5-4B19-91B4-419543A63444 Q35485630-0B5F7C8F-C111-484A-B01A-98BD00BFAD38 Q35747669-BAB7388C-0197-47A2-8ACE-EE732706F7EB Q36322893-60461346-42C1-4EFF-A857-263B3D97417F Q37003382-4B82F291-7602-4A7A-8A0F-D963FE646F7A Q37077196-4B5FCD3E-2AF5-44D5-B1EF-895C7BC64796 Q37154445-2A4083D5-25D6-447A-80CB-B4C13BBADE68 Q37189186-8C17B9E6-D6FB-42D6-9961-88797FD29CD4 Q37948516-6AF6F854-9A4F-49CB-ACF8-B8DB826CC43E Q38003594-B064AD68-BA7B-4F3A-A1F0-538B5F28DF99 Q38008634-D269F1C2-FD74-4E0D-ADEE-532563CDCC19 Q38079763-8C1B27E2-4108-4D4E-AFFB-987F12B54B78 Q38136621-464135F1-8018-4EBB-A8A5-4A705CC81ED3 Q38430611-740E0182-A8FF-481F-A3DF-8E3C2C6BAA9C Q38664558-54514E5A-4960-4CEC-B146-DFC013FD85F3 Q39231217-8B96AFFA-319D-41DE-96CB-AC08CC71D148 Q39478333-BE97BCE7-E6C8-44B3-A70C-D216288FBF4A Q40130915-CC0F5DBA-A7C3-439A-BE98-E90C6F02BBD0 Q44966912-8C1014E8-AE75-465A-89CE-5114BF718B15 Q48494474-8C0ED173-2BBC-4797-B3EF-5413103592F8 Q50653704-C4954D92-4288-4E84-AD5C-9F71D392CC30 Q50672630-A876D2BF-074B-44B6-B7BD-8390F1453B6A Q50913648-8D6BF84F-9896-4329-9F1E-9F019CCEBA63 Q51740192-219927D9-EFD5-4641-9D0E-1FB77061374E

P2860

An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk.

http://www.wikidata.org/entity/Q33925329

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

An international randomised pl ...... th raised cardiovascular risk.

@ast

An international randomised pl ...... th raised cardiovascular risk.

@en

type

label

An international randomised pl ...... th raised cardiovascular risk.

@ast

An international randomised pl ...... th raised cardiovascular risk.

@en

prefLabel

An international randomised pl ...... th raised cardiovascular risk.

@ast

An international randomised pl ...... th raised cardiovascular risk.

@en

P1433

Q33925329-FA19C764-95B1-424F-A1B9-09AFE03F477D

P1476

Q33925329-5EFF0A8A-1685-44E9-9287-DBEDBC715EB7

P2093

Q33925329-048B6727-7E2F-4FCA-8800-A28B5D42FCC3

Q33925329-3C5A42AA-B367-4047-AA16-99A3A75A8DE5

Q33925329-43982BD3-8B2D-49E9-9FCB-ECE701339E96

Q33925329-56F78899-85C8-47F0-BFE6-941B2EB1A974

Q33925329-5BFCF263-5D97-4229-9038-5FD8EAA859F8

Q33925329-5F083F28-B748-47B2-8852-5CB2D696B71B

Q33925329-705FA738-FD53-4413-9019-B378F71BF522

Q33925329-743AA884-04ED-4073-B72B-D52992239C61

Q33925329-7E9F9DBF-2B4A-4698-99BB-D0C1EF85114D

Q33925329-861F4B93-9B22-4B10-9AFD-5D285F1CA64F

P2860

Q33925329-054A4686-065C-4FDF-8328-F594FCF925E5

Q33925329-0851320E-6EF9-4549-AA30-AB0A8025E172

Q33925329-1544CEAD-6BE7-4ACC-A85B-6927225282B8

Q33925329-17A6F530-96FC-4E68-9524-EBB72E904D11

Q33925329-1FB0984F-0EC1-43B3-BA16-B6643AEC3AA8

Q33925329-246DA227-0F19-48F5-8A42-26A3B5031466

Q33925329-2E89E6A4-9CA7-4107-80CA-1DABCF0C814B

Q33925329-313B035C-CEEC-48D3-8385-820BD7975DD7

Q33925329-34A80AF8-8896-438A-98F8-A9657A91DEA0

Q33925329-3534E418-0DAB-4401-9A06-2AAE0BDA806E

P304

Q33925329-8B3ED47C-3D44-4EEE-B0AC-0DE2689FA358

P31

Q33925329-8D6ABE7B-1D1F-4D04-9E3C-BC9E1FBCCD96

P356

Q33925329-A8BFDB3B-37C7-4651-B193-5A69F8B9C6B7

P407

Q33925329-A501C623-59E7-40EF-ACCB-146572EE012B

P433

Q33925329-AB3C35D1-37CE-4A4E-A09C-994B5AC9F56F

P478

Q33925329-F6D9CD50-CD93-4898-B4FF-1D8D6CCC743F

P50

Q33925329-E5355E66-E16E-405A-B110-A97CBEF98CC1

P577

Q33925329-C64B0452-CA6E-4AFD-8DB9-61AD73E1F002

P5875

Q33925329-8729B9C9-6A82-41FD-AF18-9F5541050DC2

P698

Q33925329-E964F1F7-3DDE-4306-A4B6-4C54B532C4B6

P921

Q33925329-41561B45-C482-4636-9F7C-8C4762821727

Q33925329-4988ECB7-C073-4B7C-BACC-D56B4E891D30

P932

Q33925329-7737CCC7-E80E-4CF6-A148-24F582171A28

P356

JOURNAL.PONE.0019857

P1433

P1476

An international randomised pl ...... th raised cardiovascular risk.

@en

P2093

Anthony Rodgers

http://www.w3.org/2001/XMLSchema#string

Anushka Patel

http://www.w3.org/2001/XMLSchema#string

Bruce Neal

http://www.w3.org/2001/XMLSchema#string

Jim Neaton

http://www.w3.org/2001/XMLSchema#string

Michiel Bots

http://www.w3.org/2001/XMLSchema#string

Natasha Rafter

http://www.w3.org/2001/XMLSchema#string

Neil Poulter

http://www.w3.org/2001/XMLSchema#string

Otavio Berwanger

http://www.w3.org/2001/XMLSchema#string

P Krishnam Raju

http://www.w3.org/2001/XMLSchema#string

PILL Collaborative Group

http://www.w3.org/2001/XMLSchema#string

P2860

European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constitute

Risk factor thresholds: their existence under scrutiny

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies

Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis

A strategy to reduce cardiovascular disease by more than 80%

WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE)

Hospitalization and mortality rates from peptic ulcer disease and GI bleeding in the 1990s: relationship to sales of nonsteroidal anti-inflammatory drugs and acid suppression medications

Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report

P304

e19857

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0019857

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Diederick E Grobbee

P577

2011-05-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51197534

http://www.w3.org/2001/XMLSchema#string

P698

21647425

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio

P932

3102053

http://www.w3.org/2001/XMLSchema#string